Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interferon

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    739 result(s) found for: Interferon. Displaying page 1 of 37.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-013284-19 Sponsor Protocol Number: HINABS-ITI Start Date*: 2009-12-10
    Sponsor Name:Medical University Innsbruck
    Full Title: Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta
    Medical condition: multiple sclerosis patients with neutralizing antibodies against interferon-beta
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016678-34 Sponsor Protocol Number: CRO1456 Start Date*: 2010-04-15
    Sponsor Name:Imperial College London
    Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon
    Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001008-37 Sponsor Protocol Number: Bab1 Start Date*: 2005-11-01
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003570-89 Sponsor Protocol Number: 37559 Start Date*: 2011-12-02
    Sponsor Name:VU University Medical Center
    Full Title: The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS)
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10004504 Beta interferon therapy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000029-31 Sponsor Protocol Number: GIPF-007 Start Date*: 2005-01-28
    Sponsor Name:InterMune
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Stu...
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005751-18 Sponsor Protocol Number: QS001 Start Date*: 2006-09-07
    Sponsor Name:UCL Biomedicine R&D Unit
    Full Title: A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ...
    Medical condition: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the U...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006208-52 Sponsor Protocol Number: IFN005 Start Date*: 2009-03-09
    Sponsor Name:Helix BioPharma Cooperation
    Full Title: Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a con...
    Medical condition: cervical dysplasia (CIN I or CIN II; Pap IIID in the history, confirmed HPV+ status)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008263 Cervical dysplasia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016824-29 Sponsor Protocol Number: 1232009 Start Date*: 2010-04-06
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005545-20 Sponsor Protocol Number: IJBNMDOCASTOR Start Date*: 2014-12-23
    Sponsor Name:Institut Jules Bordet
    Full Title: The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b
    Medical condition: Progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine tumors resistant to therapy with somatostatin analogues.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006333-27 Sponsor Protocol Number: 105MS301 Start Date*: 2009-06-19
    Sponsor Name:Biogen Idec LTD
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) DE (Completed) BE (Completed) NL (Completed) ES (Completed) CZ (Completed) BG (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000453-37 Sponsor Protocol Number: 3179/AO/14 Start Date*: 2014-12-16
    Sponsor Name:Azienda Ospedaliera di Padova
    Full Title: Sequential treatment with nucleotide analogue and peg-interferon in patients with HBV-related chronic hepatitis.
    Medical condition: Hepatitis B virus (HBV)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001012-19 Sponsor Protocol Number: CFTY720DNL02T Start Date*: 2014-12-17
    Sponsor Name:VU University Medical Center
    Full Title: Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis
    Medical condition: Relapsing-remitting (RR) multiple sclerosis (MS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004040-30 Sponsor Protocol Number: EOC.NSI.11.01 Start Date*: 2013-05-24
    Sponsor Name:Ospedale Regionale di Lugano
    Full Title: Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study
    Medical condition: relapse-remitting multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003729-27 Sponsor Protocol Number: 0.8 Start Date*: 2013-11-15
    Sponsor Name:Queen Mary University of London
    Full Title: Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin
    Medical condition: Genotype 3 HCV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001419-21 Sponsor Protocol Number: TPVAHC2012 Start Date*: 2013-08-15
    Sponsor Name:Universitätsklinikum Bonn
    Full Title: An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti...
    Medical condition: Acute Hepatitis C in HIV co-infection
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001367-13 Sponsor Protocol Number: IASO_MF Start Date*: 2014-08-08
    Sponsor Name:Medizinische Universtät Wien, Universitätsklinik für Innere Medizin I
    Full Title: An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients ...
    Medical condition: Primary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteria
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000434-21 Sponsor Protocol Number: PRT-PEG-15-10880 Start Date*: 2016-11-14
    Sponsor Name:Biogen Portugal
    Full Title: PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000282-35 Sponsor Protocol Number: BO17705 Start Date*: 2004-09-29
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr...
    Medical condition: Metastatic clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7 10038415 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000162-40 Sponsor Protocol Number: IFN 001 Start Date*: 2005-09-06
    Sponsor Name:Helix Product Development (Ireland) Limited
    Full Title: Treatment of genital warts with Interferon alpha-2b Cream: a randomized, double blind, placebo-controlled study
    Medical condition: Condylomata acuminata (genital warts)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 11:42:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA